All In Biotech

Drug Trial Radar · NCT06691828

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

A Phase 1, Open-Label, 2-Period, Fixed-Sequence Study to Assess the Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance of [14C]-NX-5948 in Healthy Males

Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Nov 1, 2024

Primary completion

Nov 28, 2024

Study completion Dec 5, 2024

Sponsor

Lead sponsor
Nurix Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of \[14C\]-NX-5948. Period 1 will analyze PD (pharmacodynamics) and exploratory biomarkers. Period 2 will analyze total radioactivity and metabolite profiling.

Conditions

  • Healthy Volunteer

Interventions

  • NX-5948Drug

    NX-5948 will be given once by IV and then given once by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterize Area Under the Curve (AUC0-inf), Half-life (T1/2) after IV dosing of NX-5948Time frame: 9 weeks
  2. Evaluation of metabolite after oral dosing with [14C]-NX-5948Time frame: 9 weeks
  3. Assessment of bioavailability with oral dosing of NX-5948Time frame: 9 weeks
  4. Assessment of total radioactivity after oral dosing with NX-5948Time frame: 9 weeks
  5. Assessment of whole blood to plasma ratio for TRA after oral dosing with NX-5948Time frame: 9 weeks
  6. Characterize the Clearance (CL) after IV dosing of NX-5948Time frame: 9 weeks
  7. Characterize the Volume of distribution (Vz) after IV dosing of NX-5948Time frame: 9 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.